We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tekcapital Plc | LSE:TEK | London | Ordinary Share | GB00BKXGY798 | ORD �0.004 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.05 | 7.80 | 8.30 | 8.05 | 8.05 | 8.05 | 5,441 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Computer Programming Service | 615k | -12.75M | -0.0715 | -1.13 | 14.34M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/3/2020 08:38 | Belluscura 19% interest. That company has some game changing kit due to launch this year, so what value for that company. Currently as it stands £1 mill profit for TEK on a 15 PE is 18.75p on the share price That means 5.5p equates to a 15 PE profit rate of £300k. Just COPD costs the NHS about £10 bill per year, 30,000 deaths each year. The UK estimates 3 mill have it with about 1/3rd currently diagnosed. 1 in 8 hospital admissions in the UK is for COPD, yet it seems few know much about it. 2015 data and the problem is growing. Worldwide estimates 250 mill sufferers 3.2 mill deaths per year. Again 2015 others suggest over 300 million. So with Belluscura producing what looks like a transformational easily portable oxygen unit, which requires no oxygen tank, then it seems a big leap in convenience and costs for those that suffer with it. So to me 19% of Belluscura alone with FDA approval weeks away and launch this year, is put potentially worth far more than the share price. | philjeans | |
20/3/2020 08:23 | COPD diseases will be in the frontline herein - Lets see if sellers have cleared - | tomboyb | |
19/3/2020 23:02 | Twitter ( First Squawk U.S PRESIDENT TRUMP SAYS HAS DIRECTED FDA TO REMOVE OUTDATED RULES, BUREAUCRACIES TO SPEED CORONAVIRUS SOLUTIONS | hope67 | |
19/3/2020 14:20 | Yes added as well today excellent entry considering the prospects here near term and long term | mcrudden | |
19/3/2020 12:31 | Time to buy here now all the hot money has gone. Really good prospects for the salt and oxygen businesses at a knock down bargain price. Added. | philjeans | |
19/3/2020 11:17 | Traders out yet? - | tomboyb | |
17/3/2020 21:39 | htxps://www.dailymai | hope67 | |
17/3/2020 15:50 | I know???? - But the anti-inflammatory properties are significantly less than ibuprofen - Hence the use of paracetamol rather than Ibuprofen - | tomboyb | |
17/3/2020 15:47 | Tom paracetamol is for the temperature and works wells. | superg1 | |
17/3/2020 15:07 | Anti-inflammatories dampen down the immune system hence recovery is slow - So really Paracetamol only at the mo - | tomboyb | |
17/3/2020 15:00 | I have heard the same re ibuprofen Tom and would recommend anyone speak to a doctor about it if they are unsure | mcrudden | |
17/3/2020 14:39 | plz however dyor - | tomboyb | |
17/3/2020 14:38 | I would add that if there are possible symptoms of covid-19 in anyone, the info i have is not to take any ibuprofen - It makes the virus completely out of control - Only Paracetamol will do - | tomboyb | |
17/3/2020 14:20 | Whatever the case there will be a lot more interest in COPD diseases after this - Looking at Iran where it is really serious and the info looks horrific - Our strategy has to be on the ball from the offset - Problem is, is that Boris is changing his mind like the wind - | tomboyb | |
17/3/2020 13:47 | Just picking through Belluscura news for the last few years. I see Nigel Wray got involved re private funding 21st Feb 2019 “I invest in many small companies and I am extremely excited about Belluscura’s X-PLOR oxygen concentrator, and the benefit it will have on COPD sufferers. That is why I am backing this business.” David Poutney of Dowgate capital too, never heard off him though. | superg1 | |
17/3/2020 13:34 | Boom flying now | aimtrader2 | |
17/3/2020 13:24 | 10th Feb update "We are pleased to see the additional progress of Belluscura as it continues to strengthen its intellectual property in the oxygen therapy space to help patients afflicted with acute respiratory distress caused by the Coronavirus. Additionally, we anticipate that Belluscura is likely to receive FDA clearance for their portable oxygen concentrator within the next 90 days. " I checked re the patent and there was one filed last year, this one seems to be to add in types of disease covered. | superg1 | |
17/3/2020 13:17 | aim Ignoring hype the update was 10th Feb within 90 days. Production was already scheduled for Q4 this year, so in theory the production route and with whom is already sorted. I would hope in light of the issues they can get this type of kit available regardless of who has some. Currently about 20% of the hospital admissions require ventilators which leaves 80% who will need oxygen in some form. | superg1 | |
17/3/2020 13:09 | Interesting who was appointed to the board earlier this year. Mmmm current member of the House of Lords..... | mcrudden | |
17/3/2020 12:57 | Been loading up today heavy the FDA must be close within 90 days they said going to be crazy multibagger | aimtrader2 | |
17/3/2020 10:00 | Shocking shortage world wide very true that's why they are asking other manufacturers to start making more. Guess what xplor does and has been submitted for fda approval............ | mcrudden | |
17/3/2020 09:58 | I see smart investors have already started to join the dots here. | mcrudden | |
17/3/2020 09:52 | htxps://www.ukinvest well worth a listen this is like buying Ncyt at 13p its going to be huge when they get fda approval | hope67 | |
17/3/2020 09:40 | COPD diseases will be under the spotlight - In terms or Cornovirus UK is so inadequately prepared in terms of ventilators it is shocking - | tomboyb |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions